keyword
https://read.qxmd.com/read/29614992/a-research-study-review-of-effectiveness-of-treatments-for-psychiatric-conditions-common-to-end-stage-cancer-patients-needs-assessment-for-future-research-and-an-impassioned-plea
#21
JOURNAL ARTICLE
Ralph J Johnson
BACKGROUND: Rates of psychiatric conditions common to end-stage cancer patients (delirium, depression, anxiety disorders) remain unchanged. However, patient numbers have increased as the population has aged; indeed, cancer is a chief cause of mortality and morbidity in older populations. Effectiveness of psychiatric interventions and research to evaluate, inform, and improve interventions is critical to these patients' care. This article's intent is to report results from a recent review study on the effectiveness of interventions for psychiatric conditions common to end-stage cancer patients; the review study assessed the state of research regarding treatment effectiveness...
April 3, 2018: BMC Psychiatry
https://read.qxmd.com/read/29424319/caffeine-inhibits-angiogenesis-in-human-glioblastoma-cells-via-hifs-modulation
#22
JOURNAL ARTICLE
Grazia Maugeri, Agata Grazia D'Amico, Daniela Maria Rasà, Salvatore Saccone, Concetta Federico, Gaetano Magro, Sebastiano Cavallaro, Velia D'Agata
Caffeine represents the most used psychoactive drug in the world acting as a non-selective adenosine receptor antagonist. It exerts an anti-cancer role in glioblastoma multiforme (GBM). This neoplasia is characterized by extensive hypoxic foci triggering hypoxia-inducible factors (HIFs) expression. Among these factors, HIF-1α performs a crucial role in the induction of vascular endothelium growth factor (VEGF), a key player in angiogenesis and cell migration. In this work, we have investigated whether caffeine counteracts GBM progression by modulating hypoxic event...
February 9, 2018: Anti-cancer Agents in Medicinal Chemistry
https://read.qxmd.com/read/29407216/pharmacological-profiling-of-sigma-1-receptor-ligands-by-novel-receptor-homomer-assays
#23
JOURNAL ARTICLE
Hideaki Yano, Alessandro Bonifazi, Min Xu, Daryl A Guthrie, Stephanie N Schneck, Ara M Abramyan, Andrew D Fant, W Conrad Hong, Amy H Newman, Lei Shi
The sigma 1 receptor (σ1 R) is a structurally unique transmembrane protein that functions as a molecular chaperone in the endoplasmic reticulum (ER), and has been implicated in cancer, neuropathic pain, and psychostimulant abuse. Despite physiological and pharmacological significance, mechanistic underpinnings of structure-function relationships of σ1 R are poorly understood, and molecular interactions of selective ligands with σ1 R have not been elucidated. The recent crystallographic determination of σ1 R as a homo-trimer provides the foundation for mechanistic elucidation at the molecular level...
May 1, 2018: Neuropharmacology
https://read.qxmd.com/read/29180970/cebranopadol-a-mixed-opioid-agonist-reduces-cocaine-self-administration-through-nociceptin-opioid-and-mu-opioid-receptors
#24
JOURNAL ARTICLE
Qianwei Shen, Yulin Deng, Roberto Ciccocioppo, Nazzareno Cannella
Cocaine addiction is a widespread psychiatric condition still waiting for approved efficacious medications. Previous studies suggested that simultaneous activation of nociceptin opioid (NOP) and mu opioid (MOP) receptors could be a successful strategy to treat cocaine addiction, but the paucity of molecules co-activating both receptors with comparable potency has hampered this line of research. Cebranopadol is a non-selective opioid agonist that at nanomolar concentration activates both NOP and MOP receptors and that recently reached phase-III clinical trials for cancer pain treatment...
2017: Frontiers in Psychiatry
https://read.qxmd.com/read/28992856/cancer-related-fatigue-in-cancer-survivorship
#25
REVIEW
Chidinma C Ebede, Yongchang Jang, Carmen P Escalante
Cancer-related fatigue (CRF) significantly interferes with usual functioning because of the distressing sense of physical, emotional, and cognitive exhaustion. Assessment of CRF is important and should be performed during the initial cancer diagnosis, throughout cancer treatment, and after treatment using a fatigue scoring scale (mild-severe). The general approach to CRF management applies to cancer survivors at all fatigue levels and includes education, counseling, and other strategies. Nonpharmacologic interventions include psychosocial interventions, exercise, yoga, physically based therapy, dietary management, and sleep therapy...
November 2017: Medical Clinics of North America
https://read.qxmd.com/read/28322161/the-use-of-methylphenidate-for-physical-and-psychological-symptoms-in-cancer-patients-a-review
#26
JOURNAL ARTICLE
Beatrice Ng Andrew, Ng Chong Guan, Nik Ruzyanei Nik Jaafar
BACKGROUND: One of the goals of cancer treatment is symptoms management especially at the end stage. The common symptoms in cancer include pain, fatigue, depression and cognitive dysfunction. The available treatment options for symptom management are limited. Methylphenidate, a psychostimulant, may be of benefit for these patients. In this report, we review the use of methylphenidate for symptoms control in cancer patients. METHOD: Electronic literature search on PubMed was conducted using the following keywords: methylphenidate, cancer, carcinoma, oncology, oncological and tumour...
2018: Current Drug Targets
https://read.qxmd.com/read/28287355/donepezil-an-acetylcholinesterase-inhibitor-can-attenuate-gabapentinoid-induced-somnolence-in-patients-with-neuropathic-pain-a-retrospective-chart-review
#27
JOURNAL ARTICLE
Takamichi Kogure, Masahiko Sumitani, Kiyoshi Ikegami, Hiroaki Abe, Jun Hozumi, Reo Inoue, Kazuo Kawahara, Yoshitsugu Yamada
Donepezil, an oral acetylcholinesterase inhibitor, is used to treat Alzheimer's disease and reportedly attenuates opioid-induced sedation in patients with cancer pain. Neuropathic pain is often treated with gabapentinoids (pregabalin, gabapentin), but gabapentinoid-induced somnolence sometimes prevents patients from using these agents. We conducted a retrospective chart review of patients with neuropathic pain to examine whether donepezil is useful for gabapentinoid-induced somnolence. We investigated pain severity in 13 patients before and after taking gabapentinoids and donepezil, the degree of gabapentinoid-induced somnolence before and after starting donepezil, and gabapentinoid dose escalation after taking donepezil...
March 2017: Journal of Pain & Palliative Care Pharmacotherapy
https://read.qxmd.com/read/27478679/alcohol-interactions-with-psychostimulants-an-overview-of-animal-and-human-studies
#28
JOURNAL ARTICLE
Yusuf S Althobaiti, Youssef Sari
Alcohol consumption with psychostimulants is very common among drug addicts. There is little known about the possible pharmacological interactions between alcohol and psychostimulants. Among most commonly co-abused psychostimulants with alcohol are methamphetamine, cocaine, 3,4-methylenedioxymethamphetaminen, and nicotine. Co-abuse of alcohol with psychostimulants can lead to several neurophysiological dysfunctions such as decrease in brain antioxidant enzymes, disruption of learning and memory processes, cerebral hypo-perfusion, neurotransmitters depletion as well as potentiation of drug seeking behaviour...
June 2016: Journal of Addiction Research & Therapy
https://read.qxmd.com/read/26872373/darpp-32-from-neurotransmission-to-cancer
#29
REVIEW
Abbes Belkhiri, Shoumin Zhu, Wael El-Rifai
Dopamine and cAMP-regulated phosphoprotein Mr 32,000 (DARPP-32), also known as phosphoprotein phosphatase-1 regulatory subunit 1B (PPP1R1B), was initially discovered as a substrate of dopamine-activated protein kinase A (PKA) in the neostriatum in the brain. While phosphorylation at Thr-34 by PKA converts DARPP-32 into a potent inhibitor of protein phosphatase 1 (PP1), phosphorylation at Thr-75 transforms DARPP-32 into an inhibitor of PKA. Through regulation of DARPP-32 phosphorylation and modulation of protein phosphatase and kinase activities, DARPP-32 plays a critical role in mediating the biochemical, electrophysiological, and behavioral effects controlled by dopamine and other neurotransmitters in response to drugs of abuse and psychostimulants...
April 5, 2016: Oncotarget
https://read.qxmd.com/read/26861955/an-in-vitro-study-of-the-neurotoxic-effects-of-n-benzylpiperazine-a-designer-drug-of-abuse
#30
JOURNAL ARTICLE
Karolina Persona, Anna Polus, Joanna Góralska, Anna Gruca, Aldona Dembińska-Kieć, Wojciech Piekoszewski
Recently, the number of new psychoactive substances has significantly increased. Despite the systematic introduction of prohibition in trade of medicinal products which mimic the effects of illegal drugs, the problem concerning this group of drugs is still important although knowledge about the mechanism of action of those types of substances is scarce. This study aimed to follow the neurotoxic effect of N-benzylpiperazine (BZP), the central nervous system psychostimulant, using the human cancer LN-18 cell model...
May 2016: Neurotoxicity Research
https://read.qxmd.com/read/25896104/the-effect-of-methylphenidate-on-fatigue-in-advanced-cancer-an-aggregated-n-of-1-trial
#31
RANDOMIZED CONTROLLED TRIAL
Geoffrey K Mitchell, Janet R Hardy, Catherine J Nikles, Sue-Ann S Carmont, Hugh E Senior, Philip J Schluter, Phillip Good, David C Currow
CONTEXT: Fatigue is common in life-limiting cancer. Methylphenidate (MPH), a psychostimulant, may be a useful therapy. Gathering evidence in patients with advanced cancer can be challenging. OBJECTIVES: To determine if MPH improves cancer-related fatigue in people with advanced cancer. METHODS: N-of-1 trials are multicycle, double-blind, randomized, controlled crossover trials using standardized measures of effect in individuals. They are normally used to assess treatment effects in individuals...
September 2015: Journal of Pain and Symptom Management
https://read.qxmd.com/read/25814977/the-dopamine-imbalance-hypothesis-of-fatigue-in-multiple-sclerosis-and-other-neurological-disorders
#32
REVIEW
Ekaterina Dobryakova, Helen M Genova, John DeLuca, Glenn R Wylie
Fatigue is one of the most pervasive symptoms of multiple sclerosis (MS), and has engendered hundreds of investigations on the topic. While there is a growing literature using various methods to study fatigue, a unified theory of fatigue in MS is yet to emerge. In the current review, we synthesize findings from neuroimaging, pharmacological, neuropsychological, and immunological studies of fatigue in MS, which point to a specific hypothesis of fatigue in MS: the dopamine imbalance hypothesis. The communication between the striatum and prefrontal cortex is reliant on dopamine, a modulatory neurotransmitter...
2015: Frontiers in Neurology
https://read.qxmd.com/read/25623439/systematic-review-of-pharmacologic-and-non-pharmacologic-interventions-to-manage-cognitive-alterations-after-chemotherapy-for-breast-cancer
#33
REVIEW
Raymond J Chan, Alexandra L McCarthy, Jackie Devenish, Karen A Sullivan, Alexandre Chan
PURPOSE: Cognitive alterations are reported in breast cancer patients receiving chemotherapy. This has adverse effects on patients' quality of life and function. This systematic review investigates the effectiveness of pharmacologic and non-pharmacologic interventions to manage cognitive alterations associated with breast cancer treatment. METHODS: Medline via EBSCO host, CINAHL and Cochrane CENTRAL were searched for the period January 1999-May 2014 for prospective randomised controlled trials related to the management of chemotherapy-associated cognitive alterations...
March 2015: European Journal of Cancer
https://read.qxmd.com/read/25621777/-cancer-related-fatigue
#34
JOURNAL ARTICLE
Sonia Fatigoni, Guglielmo Fumi, Fausto Roila
Cancer-related fatigue (CRF) is a very common and distressing symptom experienced by most cancer patients, during and after treatments and also at the end of life. There is no accepted definition of CRF, because it is a multifaceted symptom that involves multiple biopsychosocial aspects. Several scales for assessing CRF have been used, unidimensional or multidimensional, but there is no agreement regarding the best instrument to measure CRF. Concerning the CRF treatment, pharmacologic and non-pharmacologic interventions have been used...
January 2015: Recenti Progressi in Medicina
https://read.qxmd.com/read/25417593/psychopharmacology-in-cancer
#35
REVIEW
Seema M Thekdi, Antolin Trinidad, Andrew Roth
Depression, anxiety, delirium, and other psychiatric symptoms are highly prevalent in the cancer setting, and pharmacological intervention is an important component in the overall psychosocial care of the patient. Psychopharmacology is also used as a primary or adjuvant treatment for the management of cancer-related symptoms stemming from the disease itself and/or its treatment, including sleep disturbance, loss of appetite, neuropathic pain, nausea, fatigue, and hot flashes. Psychiatrists, oncologists, and palliative care physicians working as members of a multidisciplinary team have the opportunity to target multiple symptoms that negatively affect a patient's quality of life with the strategic use of psychotropic medications when deemed appropriate...
January 2015: Current Psychiatry Reports
https://read.qxmd.com/read/25299141/review-of-clinical-trials-of-pharmacologic-interventions-for-cancer-related-fatigue-focus-on-psychostimulants-and-steroids
#36
REVIEW
Sriram Yennurajalingam, Eduardo Bruera
Cancer-related fatigue (CRF) is the most common and debilitating symptom in patients with cancer. Currently, there are very limited pharmacological interventions to effectively treat CRF. In this article, the authors review various pharmacological interventions for CRF and propose future direction for further research. Methylphenidate is the most studied pharmacological agent for the treatment of CRF. Various pharmacological studies have suggested benefit of corticosteroids, especially in terminally ill patients for a short period...
September 2014: Cancer Journal
https://read.qxmd.com/read/25114974/expression-of-a-splice-variant-of-cyp26b1-in-betel-quid-related-oral-cancer
#37
JOURNAL ARTICLE
Ping-Ho Chen, Ka-Wo Lee, Cheng-Chieh Hsu, Jeff Yi-Fu Chen, Yan-Hsiung Wang, Ker-Kong Chen, Hui-Min David Wang, Hurng-Wern Huang, Bin Huang
Betel quid (BQ) is a psychostimulant, an addictive substance, and a group 1 carcinogen that exhibits the potential to induce adverse health effects. Approximately, 600 million users chew a variety of BQ. Areca nut (AN) is a necessary ingredient in BQ products. Arecoline is the primary alkaloid in the AN and can be metabolized through the cytochrome P450 (CYP) superfamily by inducing reactive oxygen species (ROS) production. Full-length CYP26B1 is related to the development of oral pharyngeal cancers. We investigated whether a splice variant of CYP26B1 is associated with the occurrence of ROS related oral and pharyngeal cancer...
2014: TheScientificWorldJournal
https://read.qxmd.com/read/24951855/the-use-of-stimulant-medications-for-non-core-aspects-of-adhd-and-in-other-disorders
#38
REVIEW
Eugenia Sinita, David Coghill
Psychostimulants play a central role in the management of ADHD. Here we review the evidence pertaining to the use of methylphenidate, dexamphetamine and related amphetamine salts, the prodrug lisdexamfetamine and modafinil for the management of comorbid ADHD and non-ADHD indications. There is a growing consensus that stimulant medications are helpful at improving the emotional dysregulation and lability, and oppositional and conduct symptoms that are often associated with ADHD. There is some evidence that psychostimulants may improve outcomes in those with treatment resistant depression, reduce negative symptoms and improve cognitive performance in schizophrenia, and that methylphenidate may reduce binge eating in those with bulimia nervosa...
December 2014: Neuropharmacology
https://read.qxmd.com/read/24799492/laying-to-rest-psychostimulants-for-cancer-related-fatigue
#39
EDITORIAL
Kathryn J Ruddy, Debra Barton, Charles L Loprinzi
No abstract text is available yet for this article.
June 20, 2014: Journal of Clinical Oncology
https://read.qxmd.com/read/24733803/screening-assessment-and-management-of-fatigue-in-adult-survivors-of-cancer-an-american-society-of-clinical-oncology-clinical-practice-guideline-adaptation
#40
JOURNAL ARTICLE
Julienne E Bower, Kate Bak, Ann Berger, William Breitbart, Carmelita P Escalante, Patricia A Ganz, Hester Hill Schnipper, Christina Lacchetti, Jennifer A Ligibel, Gary H Lyman, Mohammed S Ogaily, William F Pirl, Paul B Jacobsen
PURPOSE: This guideline presents screening, assessment, and treatment approaches for the management of adult cancer survivors who are experiencing symptoms of fatigue after completion of primary treatment. METHODS: A systematic search of clinical practice guideline databases, guideline developer Web sites, and published health literature identified the pan-Canadian guideline on screening, assessment, and care of cancer-related fatigue in adults with cancer, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines In Oncology (NCCN Guidelines) for Cancer-Related Fatigue and the NCCN Guidelines for Survivorship...
June 10, 2014: Journal of Clinical Oncology
keyword
keyword
108622
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.